San Diego, Calif., April 12, 2016 – Forge Therapeutics, Inc., a biotechnology company discovering innovative therapeutics using a breakthrough drug discovery platform targeting metalloproteins, announced today that Forge will participate in the FBR Healthcare Series event being held at the JW Marriott Essex House in New York City on April 20, 2016. The theme of the event is “New Prescriptions: Innovation of Diseases and Infections” and Zachary A. Zimmerman, Ph.D., CEO of Forge, will participate in a panel discussion entitled “Showcase of Novel Technologies in Fighting Infections.”
To learn more about the conference, please visit www.fbr.com.
About Forge Therapeutics, Inc.
Forge Therapeutics, Inc. (“Forge”) is a biotechnology start-up that leverages its novel chemistry platform to develop small molecule inhibitors to target metalloproteins. Metalloproteins are proteins that require metal ions for their biological function and make up over 1/3 of the proteins in the human body. Forge uses a proprietary approach comprised of molecular modeling for rational drug design along with fundamental knowledge and expertise in bioinorganic chemistry to target metalloproteins. The name Forge Therapeutics comes from two definitions for forge: to manipulate (inhibit) a metal object (metalloprotein) and to move forward steadily with a purpose (the Forge team). Forge Therapeutics, Inc., maintains its headquarters in San Diego, California. To learn more please visit www.ForgeTherapeutics.com.
Contact:
Info@ForgeTherapeutics.com